Positive News SentimentPositive NewsNASDAQ:HURA TuHURA Biosciences (HURA) Stock Price, News & Analysis $2.81 -0.09 (-3.10%) Closing price 04:00 PM EasternExtended Trading$2.78 -0.03 (-1.21%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About TuHURA Biosciences Stock (NASDAQ:HURA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get TuHURA Biosciences alerts:Sign Up Key Stats Today's Range$2.77▼$2.9650-Day Range$2.22▼$3.2552-Week Range$1.80▼$8.40Volume259,588 shsAverage Volume791,124 shsMarket Capitalization$140.64 millionP/E RatioN/ADividend YieldN/APrice Target$12.67Consensus RatingBuy Company Overview TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. Read More TuHURA Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreHURA MarketRank™: TuHURA Biosciences scored higher than 31% of companies evaluated by MarketBeat, and ranked 813th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingTuHURA Biosciences has received a consensus rating of Buy. The company's average rating score is 3.40, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTuHURA Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about TuHURA Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioTuHURA Biosciences has a P/B Ratio of 7.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about TuHURA Biosciences' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for HURA. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTuHURA Biosciences does not currently pay a dividend.Dividend GrowthTuHURA Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for HURA. News and Social Media2.2 / 5News SentimentN/A News SentimentTuHURA Biosciences has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for TuHURA Biosciences this week, compared to 2 articles on an average week.Search Interest11 people have searched for HURA on MarketBeat in the last 30 days. This is an increase of 83% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added TuHURA Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, TuHURA Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.20% of the stock of TuHURA Biosciences is held by insiders.Percentage Held by InstitutionsOnly 0.62% of the stock of TuHURA Biosciences is held by institutions.Read more about TuHURA Biosciences' insider trading history. Receive HURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TuHURA Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HURA Stock News HeadlinesTuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment ConferenceAugust 20, 2025 | prnewswire.comTuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate UpdateAugust 14, 2025 | prnewswire.comINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.August 28 at 2:00 AM | Traders Agency (Ad)TuHURA Biosciences files to sell 4.76M shares of common stock for holdersAugust 12, 2025 | msn.comTuHURA Biosciences, Inc.'s (NASDAQ:HURA) last week's 11% decline must have disappointed retail investors who have a significant stakeAugust 12, 2025 | finance.yahoo.comTuHURA Biosciences, Inc. Common Stock (HURA) Insider ActivityJuly 14, 2025 | nasdaq.comTuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes - Seeking AlphaJuly 3, 2025 | seekingalpha.comTuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes - MorningstarJuly 3, 2025 | morningstar.comMSee More Headlines HURA Stock Analysis - Frequently Asked Questions How have HURA shares performed this year? TuHURA Biosciences' stock was trading at $4.09 at the beginning of the year. Since then, HURA shares have decreased by 31.3% and is now trading at $2.81. How were TuHURA Biosciences' earnings last quarter? TuHURA Biosciences, Inc. (NASDAQ:HURA) announced its earnings results on Thursday, August, 14th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.07. Who are TuHURA Biosciences' major shareholders? Top institutional shareholders of TuHURA Biosciences include Geode Capital Management LLC (1.33%), Suncoast Equity Management (0.24%), New York State Common Retirement Fund (0.10%) and Marshall Wace LLP (0.08%). How do I buy shares of TuHURA Biosciences? Shares of HURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/14/2025Today8/28/2025Next Earnings (Estimated)10/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HURA Previous SymbolNASDAQ:HURA CIK1498382 WebN/A Phone(813) 875-6600Fax604-608-5685EmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for TuHURA Biosciences$12.67 High Price Target$15.00 Low Price Target$11.00 Potential Upside/Downside+350.8%Consensus RatingBuy Rating Score (0-4)3.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.68 million Net MarginsN/A Pretax MarginN/A Return on Equity-248.79% Return on Assets-150.83% Debt Debt-to-Equity RatioN/A Current Ratio0.83 Quick Ratio0.83 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.38 per share Price / Book7.39Miscellaneous Outstanding Shares50,050,000Free Float49,947,000Market Cap$140.64 million OptionableN/A Beta0.04 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:HURA) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TuHURA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TuHURA Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.